Education
About Us
Working with TipRanks
Follow Us
Celldex Therapeutics Inc (CLDX)
NASDAQ:CLDX
CLDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$18.61 - $47.00
Previous CloseN/A
Volume733.18K
Average Volume (3M)743.20K
Market Cap
$1.30B
Enterprise Value$1.51B
Total Cash (Recent Filing)$28.36M
Total Debt (Recent Filing)$3.81M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
May 01, 2025EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.44
Shares Outstanding66,383,810
10 Day Avg. Volume799,275
30 Day Avg. Volume743,203
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)185.72
Price to Cash Flow (P/CF)-10.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit214.49
Enterprise Value/Ebitda-7.85
Forecast
1Y Price Target
$63.22Price Target Upside221.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Celldex News
---
Bulls Say, Bears Say
Bulls Say
Efficacy ProfileBarzolvolimab showed a potentially market-leading efficacy profile with impressive disease control observed irrespective of prior treatment.
Future Growth PotentialPipeline potential in alternative mast cell-mediated diseases for barzolvolimab and a next-gen bispecific offers strong future growth possibilities.
Unmet Medical NeedThere is significant unmet need in chronic urticaria with limited treatment options for moderate/severe disease, which positions barzolvolimab as a compelling option.
Bears Say
Competitive LandscapeThe increasingly competitive urticaria drug development landscape poses challenges for barzolvolimab's market position.
Stock PerformanceCLDX stock sits ~50% below its 1-year highs as anti-KIT mAb side effects and the increasingly competitive urticaria drug development landscape have weighed on shares.
---
Ownership Overview
0.36% Insiders
37.42% Mutual Funds
41.39% Other Institutional Investors
7.67% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CLDX FAQ
What was Celldex Therapeutics Inc’s price range in the past 12 months?
Celldex Therapeutics Inc lowest stock price was $18.61 and its highest was $47.00 in the past 12 months.
What is Celldex Therapeutics Inc’s market cap?
Celldex Therapeutics Inc’s market cap is $1.30B.
When is Celldex Therapeutics Inc’s upcoming earnings report date?
Celldex Therapeutics Inc’s upcoming earnings report date is May 01, 2025 which is in 38 days.
How were Celldex Therapeutics Inc’s earnings last quarter?
Celldex Therapeutics Inc released its earnings results on Feb 27, 2025. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.737 by $0.027.
Is Celldex Therapeutics Inc overvalued?
According to Wall Street analysts Celldex Therapeutics Inc’s price is currently Undervalued.
Does Celldex Therapeutics Inc pay dividends?
Celldex Therapeutics Inc does not currently pay dividends.
What is Celldex Therapeutics Inc’s EPS estimate?
Celldex Therapeutics Inc’s EPS estimate is -0.76.
How many shares outstanding does Celldex Therapeutics Inc have?
Celldex Therapeutics Inc has 66,383,810 shares outstanding.
What happened to Celldex Therapeutics Inc’s price movement after its last earnings report?
Celldex Therapeutics Inc reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.737. Following the earnings report the stock price went up 1.28%.
Which hedge fund is a major shareholder of Celldex Therapeutics Inc?
Currently, no hedge funds are holding shares in CLDX
---
Celldex Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.22 (221.89% Upside)
$63.22 (221.89% Upside)
Blogger Sentiment
Bullish
CLDX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 249.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.10%
12-Months-Change
Fundamentals
Return on Equity
-26.84%
Trailing 12-Months
Asset Growth
70.17%
Trailing 12-Months
Company Description
Celldex Therapeutics Inc
Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
---
CLDX Stock 12 Month Forecast
Average Price Target
$63.22
▲(221.89% Upside)
Technical Analysis
Best Analysts Covering CLDX
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+86.59%
reiterated a buy rating 2 months ago
Copying Kristen Kluska's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +86.59% per trade.
---